Story

The Full Story

Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

In 2017, Reckitt bought Mead Johnson for $16.6bn and called it transformational. Eight years and three CEOs later, that deal sits at the centre of every chart on this page: a $6.7bn impairment in 2019, a partial sale of IFCN China in 2021, a $1.0bn goodwill impairment in 2023, a $1.05bn impairment for IFCN/Biofreeze in 2024, an NEC litigation overhang from 2024, and an "all strategic options" review of Mead Johnson that as of FY2025 still has no buyer. The story management tells today — focus on 11 Powerbrands, exit Essential Home (done Dec 2025), exit Mead Johnson (in progress), get fixed costs below 19% by 2027 — is in essence the unwinding of the 2010s portfolio. Credibility is repairing. The 2025 print (Core +5.2%, group AOP margin 24.9%, Essential Home sold for an enterprise value of up to $4.8bn) is the first year in which the words and the numbers lined up cleanly. But six years of strategy resets and a Mead Johnson book that has been written down repeatedly mean the bar for "trust the guide" should still be lower than for a normal staples compounder.

1. The Narrative Arc

The arc is unmistakable: a five-year unwinding of the 2010s deal-driven Reckitt back to the consumer-health-and-hygiene Powerbrand business it described itself as in 2007. Four of the years in this table contain a Mead Johnson-related write-down or disposal milestone. The current management's repositioning is, mechanically, a deconsolidation of what Rakesh Kapoor assembled.

2. What Management Emphasized — and Then Stopped Emphasizing

Counts below come from manual review of the chairman/CEO statements in each annual report and the FY full-year results presentation transcripts (FY2019, FY2020, FY2021, FY2022 letters/transcripts; FY2023, FY2024, FY2025 transcripts). Intensity is on a 0–5 scale (5 = central pillar of the narrative; 0 = absent or barely mentioned).

The pattern is sharp:

• What got dropped quietly: the Narasimhan-era purpose vocabulary ("our fight", "rejuvenating sustainable growth", "good house in a great neighbourhood") faded out completely between FY2023 and FY2025. So did "Hygiene Home" / "Essential Home as a core part of Reckitt", which moved from a co-equal segment to a divested one in 18 months. Sustainability went from a five-page chairman's anchor (FY2020) to a few sentences (FY2025).
• What replaced them: Powerbrands (now numbered: 11), Emerging Markets, Fuel for Growth, capital returns, generative AI, and "winning playbook" / "category playbook." This is the Licht/Eisenhardt vocabulary. It is more numeric and more operational than what came before.
• What stayed: innovation, gross margin discipline, Lysol/Dettol/Durex/Mucinex/Finish as anchor brands. The brand mythology is constant; the strategic wrapper around it is not.

3. Risk Evolution

Risks are coded from each AR's principal-risk register and from disclosures in the corresponding year's results call. Intensity is 0–5 (5 = top-tier disclosed risk with active mitigation programme; 0 = absent).

What's important here is the sequencing of new risks:

• Mead Johnson never went away. It was a peak risk in 2019 ($6.6bn impairment), faded slightly through 2020–2022 as management said integration was "on track," then came back as the dominant single risk in 2024 when (a) the NEC litigation hit, (b) the Mt Vernon tornado disabled the lead Nutrition factory, and (c) management itself put MJN on the divestment list. Eight years after the deal closed, MJN is still the company's biggest individual risk line.
• NEC litigation appeared from nothing in 2023–2024. A March 2024 Illinois jury awarded $60m against Reckitt's Mead Johnson unit; a July 2024 jury ordered nearly $500m against Abbott in a parallel case. Bloomberg Intelligence flagged $2.5bn potential exposure. A November 2024 St Louis defence verdict took the worst-case off the table. The risk is still live in 2025 disclosures but no longer existential.
• Tariffs / US sourcing went from absent to a top-tier 2024–2025 risk in one year. Management's response on the FY2024 call ("we source most of our products from the regions we operate in… not as exposed as many other industries") is the calmest version of any tariff comment from any UK staples company in this cycle. That's a defensible claim — most of US revenue is locally manufactured — but it is also a claim, not a tested outcome.
• What dropped out: the Korean humidifier sanitiser legacy (resolved in 2023 with full provisioning), most of the COVID-specific risk language, and a 2022–2023 Middle East under-reporting investigation that was reported but never escalated to a principal risk.

4. How They Handled Bad News

The pattern across the cycle: Reckitt's bad news arrives as one big number plus a one-line cause attribution — and management almost never restates the underlying strategy until forced to.

Two patterns are worth flagging:

1. The Mead Johnson story repeated three times before management accepted the verdict. In 2019 the $6.6bn impairment was framed as one-off (China birth rates). In 2023 the $1.0bn further impairment was framed as category dynamics. In 2024 management changed framing — "all strategic options" — and the same brand was finally up for sale. Each impairment was presented in isolation; the cumulative narrative was never spoken from the stage. As of the FY2025 call, MJN's own outlook ("trading well… expect another good year") still doesn't quite reconcile with management actively shopping it.
2. Narasimhan's exit was handled as a non-event. The September 2022 trading update did not initially mention strategic implications. The FY2022 chairman's statement thanked him for his "important contribution" and named Nicandro Durante as interim. Public-domain reporting later established Narasimhan went directly to Starbucks (announced March 2023, with a $28m sign-on package); the framing of "personal and family reasons" was thin even at the time. The board took a full year to name a permanent successor (Licht, Oct 2023). For a FTSE-100 company in the middle of a multi-year transformation, that's a long handover gap and the chair's commentary minimised it.

The contrast: when the November 2024 NEC defence verdict came in, management let the verdict speak — no euphemisms, no expanded narrative, just an acknowledgement that the litigation "remains live" and the underlying brand is sound. That tone is more credible than the 2019–2023 pattern.

5. Guidance Track Record

Each row is a promise that mattered to valuation — initial growth, margin, EPS, programme, and capital-return targets. "Status" is judged against the most recent reported actuals.

The 6.5 is a deliberate compromise. On the operating side — Fuel for Growth, Essential Home divestment, Core Reckitt revenue growth, capital returns — the current team has hit or beaten everything they have set since taking over in late 2023. That is genuinely better than the prior cycle. But the 7-9% medium-term EPS commitment from 2020 was missed by a margin no other rationale can paper over (six-year EPS CAGR of ~0.5% in USD), and the Mead Johnson story has been incrementally rewritten three times. Until MJN is actually sold or held with a clean rationale, the rating cannot move much above the staples-sector average.

6. What the Story Is Now

What has been de-risked

• Portfolio simplification is real. Essential Home is sold and the cash is in the bank. The 2024 strategy update has not been quietly dropped after one cycle — it has been executed.
• Cost programme is ahead of plan. Fuel for Growth delivered 150bps in 2025 versus a 100bps trajectory; management raised the 2027 fixed-cost target rather than declaring victory. That is the right behaviour for a credibility-rebuilding story.
• NEC litigation tail risk is no longer existential. The November 2024 St Louis defence verdict, plus the relative magnitude of the cases left, mean MJN can be sold or run without a binary legal overhang. It still matters; it no longer dictates the outcome.
• Emerging Markets is genuinely working. China up double digits for ten sequential quarters, India high-single-digit, Latin America executional improvements. EM at 14.6% LFL growth in 2025 with 210bps of margin expansion is the strongest single number in the FY2025 print.

What still looks stretched

• Mead Johnson. Management is shopping it, MJN itself is "trading well", and price discovery is the open question. A clean exit is not yet evidenced — and the litigation overhang, however reduced, will price into any sale.
• Europe. Volumes were down 3.1% in 2025; promotional intensity is "excessive." Management's own framing for 2026 is that Europe stays tough. The Core Reckitt 4-5% guide assumes EM bails out Europe again. That worked in 2025; it is not guaranteed in 2026.
• EPS arithmetic. The 2026 guide (EPS dilution from EH disposal acknowledged, special dividend, share consolidation, buyback continuation) is a complex moving target. EPS sustainability over the medium term is still the most testable claim in the deck — and the one with the worst recent track record.
• Stranded costs. "Largely offset" the EH stranded costs is hedged language. Management explicitly confirmed group fixed-cost ratio rises in 2026 before falling in 2027. There is execution risk between the FY2024 350bps cost ambition and the steady-state P&L.

What the reader should believe vs discount